When should you fire the founder?

William Bains

J Commer Biotechnol 13: 139-149; doi:10.1057/palgrave.jcb.3050050

Abstract | Full Text | PDF

Constructing a processual model of communication in new product development from a multiple case study of biotechnology SMEs

Jennifer Frahm, David C Ireland and Damian Hine

J Commer Biotechnol 13: 151-161; doi:10.1057/palgrave.jcb.3050049

Abstract | Full Text | PDF

A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape

Gareth Williams

J Commer Biotechnol 13: 163-175; doi:10.1057/palgrave.jcb.3050058

Abstract | Full Text | PDF

Measuring performance of field-medical programmes: Medical science liaison metrics consensus

Jane Chin

J Commer Biotechnol 13: 177-182; doi:10.1057/palgrave.jcb.3050057

Abstract | Full Text | PDF

The commercialisation of bioinformatics and the threat of open-source software

Joseph F Greco

J Commer Biotechnol 13: 183-194; doi:10.1057/palgrave.jcb.3050051

Abstract | Full Text | PDF

Intellectual property issues in nanotechnology

Lars Genieser and Michael Gollin

J Commer Biotechnol 13: 195-198; doi:10.1057/palgrave.jcb.3050052

Abstract | Full Text | PDF

Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost?

Pedro Reinares Lara and Emma Gutierrez de Mesa

J Commer Biotechnol 13: 199-207; doi:10.1057/palgrave.jcb.3050054

Abstract | Full Text | PDF

Changing hopes and concerns about gene therapy in Japan

Darryl Macer, Yoshihiro Okada, Makoto Nakagawa, MaryAnn Chen Ng and Masakazu Inaba

J Commer Biotechnol 13: 209-222; doi:10.1057/palgrave.jcb.3050055

Abstract | Full Text | PDF

Legal and regulatory update

J Commer Biotechnol 13: 223-231; doi:10.1057/palgrave.jcb.3050048

Abstract | Full Text | PDF